Press Release Contact

Press release:
ReEngage Therapeutics Launches to Develop ACSS2 Inhibitor Compounds for Cancer Indications
May 21, 2024, 13:00 GMT

For questions about this press release, please contact the person or organization listed below.

Thomas Kim
ReEngage Therapeutics Inc.
Visit us on social media:
X
LinkedIn